Becton, Dickinson and Company (BDX) is a major player in the medical technology industry, with a market cap of $54.2 billion. Headquartered in Franklin Lakes, New Jersey, the company is known for developing, manufacturing, and selling a wide range of medical devices, laboratory equipment, and diagnostic products used in healthcare, research, and clinical settings. BD operates through three key segments: BD Medical, BD Life Sciences, and BD Interventional, serving a global customer base that includes hospitals, laboratories, and pharmaceutical companies.
Despite its strong presence in the industry, BDX stock has underperformed the broader market in the past year. Over the last 52 weeks, BDX stock has decreased by 16.9%, while the S&P 500 Index has gained 14.5%. Year-to-date, the company’s shares have declined by 15.3%, in contrast to the 16.5% rise of the S&P 500. Additionally, BDX stock has lagged behind the Health Care Select Sector SPDR Fund’s 3.8% increase over the past year and 11.1% return in 2025.
However, there is some positive news for the company. BDX recently reported its fourth-quarter earnings, which led to a marginal increase in its share price. The company posted revenue of $5.9 billion, an 8.3% year-over-year increase, driven by strong demand in its medical and interventional segments. BDX also reported an adjusted EPS of $3.96, up from $3.81 the previous year, which slightly exceeded expectations. Looking ahead, the company provided guidance for fiscal 2026 adjusted EPS between $14.75 and $15.05.
Analysts are optimistic about BDX’s future performance, with expectations for adjusted EPS to grow by 3% year-over-year to $14.83 for the fiscal year ending in September 2026. The company has a history of beating consensus estimates, with four consecutive quarters of earnings surprises. Among the 16 analysts covering the stock, the consensus rating is a “Moderate Buy,” with six “Strong Buy” ratings, one “Moderate Buy,” and nine “Holds.”
In a recent update, Piper Sandler analyst Jason Bednar reiterated a “Hold” rating on Becton Dickinson and maintained a $200 price target on the stock. This indicates a level of caution in the short term, but overall, the outlook for BDX remains positive in the eyes of analysts and investors alike.
